Tailoring Extended-Release ADHD Treatment Around the Clock

"Tailoring Extended-Release ADHD Treatment Around the Clock" closes the series by tailoring extended-release strategies to the moments patients struggle with most, from chaotic mornings to evening crashes.

In the program's final discussion, the panel explores how different extended-release technologies can be tailored to specific patient concerns. One panelist recalls the promise of long-acting nighttime stimulants for households in early-morning chaos, but cautions that early coverage should never come at the expense of coverage later in the day, since patients need consistent control across the entire dosing window. The panel offers a practical way to tell a medication crash from simple undertreated ADHD: symptoms that spike well beyond baseline and resolve within about ninety minutes suggest a crash, sometimes called the "bewitching hour," while symptoms that settle back to baseline and stay there the rest of the evening suggest the ADHD itself is undertreated.

The panel reviews how a prodrug stimulant needs sixty to ninety minutes to activate once it reaches the upper gastrointestinal tract, meaning patients cannot take it moments before school or a meeting and expect quick relief, nor make up a missed dose a few hours later. Many newer extended-release formulations now offer onset under thirty minutes, while a transdermal dexamphetamine patch, with a one-to-two-hour onset, suits patients with gastrointestinal issues, inconsistent breakfast habits, or a need for flexible removal timing. The panel emphasizes asking about onset speed, adherence patterns, and how quickly relief is needed to guide formulation choice, including chewable, liquid, or dissolvable sprinkle options that allow dose titration by the amount consumed.

The panel also discusses backup planning: patients on a nighttime methylphenidate risk waking up untreated if they forget an evening dose, so keeping a backup formulation on hand can prevent a lost day. When switching for tolerability, the panel favors staying within the same drug family, methylphenidate or amphetamine, before crossing to the other class, since proven efficacy often carries over even when the delivery system changes.

Thank you for watching this Psychiatric Times Peer Exchange series on attention-deficit/hyperactivity disorder in adults. Please subscribe to our eNewsletter for information on upcoming video series.